SKYE Skye Bioscience, Inc.
Skye Bioscience, Inc. (SKYE) is expected to report earnings on November 13, 2026, after the market close. The consensus earnings estimate is a loss of $0.29 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -41.7% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Skye Bioscience, Inc.
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.
Sector
Healthcare
Industry
Biotechnology